Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plecanatide in IBS-C (Study 2)
NCT02493452Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jun 2015
- Primary completion
- Nov 2016
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of plecanatide in irritable bowel syndrome (IBS) (3 arms), sponsored by Valeant Pharmaceuticals. Primary endpoints: Number of Overall Responders at 12 weeks, Number of Abdominal Pain Responders at 12 weeks and 1 more. Started Jun 2015; status: completed.
02
Drugs
plecanatide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT02493452.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02493452.